Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus CEFIZOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus CEFIZOX.
CEFACLOR vs CEFIZOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
250-500 mg orally every 8 hours
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCefaclor + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."
Clinical Note
moderateWarfarin + Cefaclor
"Warfarin may increase the anticoagulant activities of Cefaclor."
Clinical Note
moderatePhenprocoumon + Cefaclor
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefaclor."